IP Library Granted Patent US 9,447,432
Granted Patent B2
US 9,447,432 · App. 13/641,370 · Granted Sep 20, 2016

Method for producing induced pluripotent stem cells

Inventors: Keiichi Fukuda (Tokyo, JP); Shinsuke Yuasa (Tokyo, JP); Tomohisa Seki (Tokyo, JP); Mamoru Hasegawa (Tsukuba, JP)
Assignees: Keio University; DNAVEC Corporation
C12N15/86C12N5/0696C12N2501/2302C12N2501/515C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2502/13C12N2506/11C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,447,432
App. No.
13/641,370
Granted
Sep 20, 2016
Kind
B2
Abstract

An object of the present invention is to provide methods for producing iPS cells with low invasivity and high efficiency. The iPS cells can be produced with high efficiency using a method comprising the steps of culturing mononuclear cells derived from peripheral blood for 3 to 14 days in the presence of anti-CD3 antibody, and subjecting the cultured mononuclear cells to dedifferentiation.

Claims (8)

1. A method for producing a mammalian induced pluripotent stem cell comprising:

(i) culturing a population consisting essentially of mammalian mononuclear cells isolated from peripheral blood for 3 to 14 days in the presence of anti-CD3 antibody and interleukin 2; and

(ii) subjecting the cultured mononuclear cells to dedifferentiation by introduction of retroviral or Sendai viral vector(s) encoding Oct-4, Sox-2, Klf-4, and c-myc; and

(iii) culturing the cells in (ii) under embryonic stem (ES) cell culture conditions to produce an induced pluripotent stem cell.

2. The method for producing a mammalian induced pluripotent stem cell according to claim 1 , wherein:

the recombinant expression vector is a Sendai virus vector.

3. The method for producing a mammalian induced pluripotent stem cell according to claim 1 , wherein step (iii) comprises culturing the dedifferentiated mononuclear cells for 14 to 25 days in the presence of a growth factor.

4. The method for producing a mammalian induced pluripotent stem cell according to claim 1 , wherein said peripheral blood is isolated from a human.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2019
From: KEIO UNIVERSITY
To: HEARTSEED INC.
Reel/Frame 050359/0421 →
CHANGE OF NAME Recorded Sep 12, 2019
From: DNAVEC CORPORATION
To: ID PHARMA CO., LTD.
Reel/Frame 050364/0183 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2013
From: FUKUDA, KEIICHI; YUASA, SHINSUKE; SEKI, TOMOHISA
To: KEIO UNIVERSITY
Reel/Frame 029568/0842 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2013
From: HASEGAWA, MAMORU
To: DNAVEC CORPORATION
Reel/Frame 029568/0855 →
Priority Claims (1)
JP 2010-095404 · Apr 16, 2010 · national
Continuity (1)
Related Publication 20130189786A1 · Jul 25, 2013